Want to join the conversation?
$LLY said it decided to discontinue developing basal insulin peglispro, a potential treatment for type 1 & 2 diabetes in order to focus R&D efforts on other assets in its portfolio. This decision will result in a 4Q15 charge to $LLY's GAAP & non-GAAP R&D expense of about $0.03/share (after-tax). $LLY's previously issued guidance remains unchanged.
$EXTR has been on an interesting uptrend, fundamentals kinda tricky but solid technical. Earnings 5th
Wow! $MCD scores again.